Global RNAi Therapeutics Market Opportunities and Forecast 2020-2027

  • DLR2865
  • 01 December, 2021
  • Pharma & Healthcare
  • Pages: 120
  • Global
Global RNAi Therapeutics Market, By Technology (LED, Halogen, Xenon), ByVehicle Type (Passenger cars, Commercial vehicles, Two-wheeler), By Application (Interior lighting, Side lighting, Rear lighting, Front lighting/headlamps) and opportunities and forecast 2020-2027

RNAi Therapeutics Market Overview

Cancer diagnosis and treatment are presently undergoing a shift with the incorporation of RNAi techniques in personalized drugs and molecular diagnostics. The availability of high output techniques for the identification of altered cellular molecules and metabolites allows the utilization of RNAi techniques in various cancer diagnosis and targeting approaches. For diagnostic functions, little busy RNAs (siRNA) or microRNAs (miRNA) may be used. The commercial handiness of siRNAs to silence nearly any gene within the human ordering is dramatically fast the pace of molecular identification and medical specialty analysis. Thus, increasing the appliance of RNAi in molecular identification and its viability as a therapeutic technique is predicted to drive the expansion of the RNAi market throughout the forecast amount.

FDA explains producing standards and different obliging problems because the major reasons for this declining trend. This could impede the expansion of the RNAi therapeutics, particularly since the miRNAs and siRNAs comprise the relatively new field of genetic drugs, whereby they'll need additional intense clinical trials. The extremely intensive clinical trials effectively end in low approval rates of medication. This might mean that the tight guidelines are going to be a major restraint on the growth of the market.

Report Metric Details
Market size available for years 2019–2027
Base year considered 2019
Forecast period 2020–2027
Forecast unit Value (USD Million)
Segments covered Technology ,Vehicle Type, Application, and Region
Regions covered North America (the U.S. and Canada), Europe (UK, Germany, France, Italy, Spain, Russia, Rest of Europe), Asia-Pacific (China, India, Japan, Australia, South East Asia, Rest of Asia Pacific), Latin America and the Middle East and Africa (Brazil, Saudi Arabia, UAE, Rest of LAMEA)
Companies covered Pfizer CentreOne,Sanofi,GlaxoSmithKline, TianjinPharmaceutical Group Co. Ltd., Guangdong VTR Bio-Tech Co. Ltd, Guangdong VTR Bio-Tech Co. Ltd, Symbiotec Pharmalab, SunPharmaceutical, Cipla, Hovione, Shandong Xinhua Pharmaceutical Company Lit, Steroid.


The covid-19 Impact on RNAi Therapeutics Market:

Like several different industries, COVID-19 badly knocked the electronic and semiconductor trade. This new event has compact nearly 230 countries in exactly a couple of weeks, leading to the forced conclusion of producing and transportation activities at intervals and across the countries. This has directly affected the expansion of the sector. It's calculable that COVID-19 to depart over USD thirty billion impacts on the physics and semiconductor trade. The arena is majorly affected thanks to transport restrictions on major physics and semiconductor staple suppliers. However, the rising want for semiconductors in many industries can supply fast market recovery over the longer-term amount.
 
RNAi Therapeutics Market Segment Overview



By Molecule type ,the small interfering RNAs (siRNA) segment command a larger share of the market in forecast period, Growth of this section is attributed to the increasing preference for small interfering RNAs for drug development and growing variety of analysis partnerships. Further, the MicroRNA (miRNA) section is expected to register higher CAGR within the global RNAi therapeutics market throughout the forecast period.
 
By Application,  the oncology segment accounted for the largest share of  the international RNAi global market due to increasing preference for RNAi therapies for the treatment of cancer. Moreover, growing variety of analysis collaborations within the field of oncology are projected to drive the segment growth by 2027. However, cardiovascular disorders segment is estimated to register the best CAGR intravenous market throughout the forecast period.
 
By Route of administration,  the pulmonic delivery segment accounted for the largest share of the world RNAi medicine market. However, blood vessel injections segment is estimated to register the best CAGR within the market throughout the forecast period. significant variety or product launches and better adoption of blood vessel injection are probably to possess a positive impact on the section growth.
 
By End user, The analysis and academic laboratories segment period the largest share of the market in forecast period and is predicted to register the best CAGR period the forecast control.
 
Market Analysis, Insights and Forecast – By Molecule Type
·       Small Interfering RNAs (siRNA)
·       MicroRNA (miRNA)

Market Analysis, Insights and Forecast – By Application
·       Oncology
·       Cardiovascular
·       Respiratory Disorders
·       Renal Diseases
·       Genetic Disorders
·       Neurodegenerative Disorders
·       Infectious Diseases
·       Others
 
Market Analysis, Insights and Forecast - By Route of Administration
·       Pulmonary Delivery
·       Intravenous Injections
·       Intradermal Injections
·       Intraperitoneal Injections
·       Others
 
Market Analysis, Insights and Forecast - By End User
·       Research and Academic Laboratories
·       Hospitals
·       Diagnostic Laboratories

RNAi Therapeutics Market Regional Overview

Region-wise, in terms of regions ,The U.S. has a number of RNAi therapeutics that are in developmental pipelines. Variety of biotechnology firms have created significantly high investments for RNAi therapeutic development. huge pharmaceutical developers have entered into collaboration agreements or licensing deals with variety of smaller corporations in an endeavor to make the most the expected growth in revenue that this market will have over the forecast period.

RNAi Therapeutics-market, By Geography

·       North America (US & Canada)
·       Europe (UK, Germany, France, Italy, Spain, & Rest of Europe)
·       Asia-Pacific (Japan, China, India, Australia, & South Korea, & Rest of Asia-Pacific)
·       LAMEA (Brazil, Saudi Arabia, UAE & Rest of LAMEA)
 
RNAi Therapeutics Market Competitor overview

Some key developments and strategies adopted by manufacturers in the RNAi Therapeutics are highlighted below.

·       In 2020, Blackstone Life Sciences, a worldwide investment company, and Alnylam pharmaceuticals, Inc., investment company RNAi therapeutics company, announced the closing of a $2 billion strategic finance collaboration to accelerate the advancement and development of RNAi therapeutics.

RNAi Therapeutics Market, Key Players -

·       Alnylam Pharmaceuticals, Inc.
·       Sanofi
·       Olix Pharmaceuticals, Inc.
·       Glaxosmithkline Plc.
·       Benitec Biopharma
·       Arbutus Biopharma Corporation
·       Silence Therapeutics
·       Rexahn Pharmaceuticals, Inc.
·       Arrowhead Pharmaceuticals, Inc
·       Quark
 
 
 
 

Frequently Asked Questions (FAQ) :

Q1. What is the total CAGR expected to be recorded for the RNAi Therapeutics market during the forecast period?

A. RNAi Therapeutics market is expected to record a CAGR of ~ 8.9% during the forecast period.

Q2. Which segment is projected to hold the largest share in the RNAi Therapeutics Market?

A. Small interfering RNAs (siRNA) segment is projected to hold the largest share in the RNAi Therapeutics Market.

Q3. What are the driving factors for the RNAi Therapeutics market?

A. Increasing the approach of utilized for drug development ,Increasing investments in RNAi therapy development ,these are main factors driving the growth of automotive lighting market.

Q4. Which Segments are covered in the RNAi Therapeutics market report?

A. Molecule Type,Application,Route of Administration,End User,and Region, these segments are covered in the RNAi Therapeutics market report

Q5. Which are the prominent players offering Fuel Dispenser?

A. Alnylam Pharmaceuticals, Inc.,Sanofi ,Olix Pharmaceuticals, Inc.,Glaxosmithkline Plc.,Benitec Biopharma,Arbutus Biopharma Corporation,Silence Therapeutics,Rexahn Pharmaceuticals, Inc.,Arrowhead Pharmaceuticals, Inc.,Quark
RNAi Therapeutics Market Study Global Market Analysis, Insights and Forecast, 2020-2027

    1. Introduction

    • 1.1. Research Scope
    • 1.2. Market Segmentation
    • 1.3. Research Methodology
    • 1.4. Definitions and Assumptions

    2. Executive Summary

      3. Market Dynamics

      • 3.1. Market Drivers
      • 3.2. Market Restraints
      • 3.3. Market Opportunities

      4. Key Insights

      • 4.1. Key Emerging Trends – For Major Countries
      • 4.2. Latest Technological Advancement
      • 4.3. Regulatory Landscape
      • 4.4. Industry SWOT Analysis
      • 4.5. Porters Five Forces Analysis

      5. Global RNAi Therapeutics Market Analysis (USD Billion), Insights and Forecast, 2020-2027

      • 5.1. Key Findings / Summary
      • 5.2. Market Analysis, Insights and Forecast – By Molecule Type
        • 5.2.1. Small Interfering RNAs (siRNA)
        • 5.2.2. MicroRNA (miRNA)
      • 5.3. Market Analysis, Insights and Forecast – By Application
        • 5.3.1. Oncology
        • 5.3.2. Cardiovascular
        • 5.3.3. Respiratory Disorders
        • 5.3.4. Renal Diseases
        • 5.3.5. Genetic Disorders
        • 5.3.6. Neurodegenerative Disorders
        • 5.3.7. Infectious Diseases
        • 5.3.8. Others
      • 5.4. Market Analysis, Insights and Forecast – By Route of Administration
        • 5.4.1. Pulmonary Delivery
        • 5.4.2. Intravenous Injections
        • 5.4.3. Intradermal Injections
        • 5.4.4. Intraperitoneal Injections
        • 5.4.5. Others
      • 5.5. Market Analysis, Insights and Forecast – By End User
        • 5.5.1. Research and Academic Laboratories
        • 5.5.2. Hospitals
        • 5.5.3. Diagnostic Laboratories
      • 5.6. Market Analysis, Insights and Forecast – By Region
        • 5.6.1. North America
        • 5.6.2. Europe
        • 5.6.3. Asia Pacific
        • 5.6.4. Latin America, Middle East, and Africa

      6. North America RNAi Therapeutics Market Analysis (USD Billion), Insights and Forecast, 2020-2027

      • 6.1. Key Findings / Summary
      • 6.2. Market Analysis, Insights and Forecast – By Molecule Type
        • 6.2.1. Small Interfering RNAs (siRNA)
        • 6.2.2. MicroRNA (miRNA)
      • 6.3. Market Analysis, Insights and Forecast – By Application
        • 6.3.1. Oncology
        • 6.3.2. Cardiovascular
        • 6.3.3. Respiratory Disorders
        • 6.3.4. Renal Diseases
        • 6.3.5. Genetic Disorders
        • 6.3.6. Neurodegenerative Disorders
        • 6.3.7. Infectious Diseases
        • 6.3.8. Others
      • 6.4. Market Analysis, Insights and Forecast – By Route of Administration
        • 6.4.1. Pulmonary Delivery
        • 6.4.2. Intravenous Injections
        • 6.4.3. Intradermal Injections
        • 6.4.4. Intraperitoneal Injections
        • 6.4.5. Others
      • 6.5. Market Analysis, Insights and Forecast – By End User
        • 6.5.1. Research and Academic Laboratories
        • 6.5.2. Hospitals
        • 6.5.3. Diagnostic Laboratories
      • 6.6. Market Analysis, Insights and Forecast – By Country
        • 6.6.1. UK
        • 6.6.2. Germany
        • 6.6.3. France
        • 6.6.4. Italy
        • 6.6.5. Spain
        • 6.6.6. Russia
        • 6.6.7. Rest of Europe

      7. Asia Pacific RNAi Therapeutics Market Analysis (USD Billion), Insights and Forecast, 2020-2027

      • 7.1. Key Findings / Summary
      • 7.2. Market Analysis, Insights and Forecast – By Molecule Type
        • 7.2.1. Small Interfering RNAs (siRNA)
        • 7.2.2. MicroRNA (miRNA)
      • 7.3. Market Analysis, Insights and Forecast – By Application
        • 7.3.1. Oncology
        • 7.3.2. Cardiovascular
        • 7.3.3. Respiratory Disorders
        • 7.3.4. Renal Diseases
        • 7.3.5. Genetic Disorders
        • 7.3.6. Neurodegenerative Disorders
        • 7.3.7. Infectious Diseases
        • 7.3.8. Others
      • 7.4. Market Analysis, Insights and Forecast – By Route of Administration
        • 7.4.1. Pulmonary Delivery
        • 7.4.2. Intravenous Injections
        • 7.4.3. Intradermal Injections
        • 7.4.4. Intraperitoneal Injections
        • 7.4.5. Others
      • 7.5. Market Analysis, Insights and Forecast – By End User
        • 7.5.1. Research and Academic Laboratories
        • 7.5.2. Hospitals
        • 7.5.3. Diagnostic Laboratories
      • 7.6. Market Analysis, Insights and Forecast – By Country
        • 7.6.1. China
        • 7.6.2. India
        • 7.6.3. Japan
        • 7.6.4. Australia
        • 7.6.5. South East Asia
        • 7.6.6. Rest of Asia Pacific

      8. Latin America, Middle East, and Africa RNAi Therapeutics Market Analysis (USD Billion), Insights and Forecast, 2020-2027

      • 8.1. Key Findings / Summary
      • 8.2. Market Analysis, Insights and Forecast – By Molecule Type
        • 8.2.1. Small Interfering RNAs (siRNA)
        • 8.2.2. MicroRNA (miRNA)
      • 8.3. Market Analysis, Insights and Forecast – By Application
        • 8.3.1. Oncology
        • 8.3.2. Cardiovascular
        • 8.3.3. Respiratory Disorders
        • 8.3.4. Renal Diseases
        • 8.3.5. Genetic Disorders
        • 8.3.6. Neurodegenerative Disorders
        • 8.3.7. Infectious Diseases
        • 8.3.8. Others
      • 8.4. Market Analysis, Insights and Forecast – By Route of Administration
        • 8.4.1. Pulmonary Delivery
        • 8.4.2. Intravenous Injections
        • 8.4.3. Intradermal Injections
        • 8.4.4. Intraperitoneal Injections
        • 8.4.5. Others
      • 8.5. Market Analysis, Insights and Forecast – By End User
        • 8.5.1. Research and Academic Laboratories
        • 8.5.2. Hospitals
        • 8.5.3. Diagnostic Laboratories
      • 8.6. Market Analysis, Insights and Forecast – By Country
        • 8.6.1. Brazil
        • 8.6.2. Saudi Arabia
        • 8.6.3. UAE
        • 8.6.4. Rest of LAMEA

      9. Competitive Analysis

      • 9.1. Company Market Share Analysis, 2018
      • 9.2. Key Industry Developments
      • 9.3. Company Profile
      • 9.4. Alnylam Pharmaceuticals, Inc.
        • 9.4.1. Business Overview
        • 9.4.2. Segment 1 & Service Offering
        • 9.4.3. Overall Revenue
        • 9.4.4. Geographic Presence
        • 9.4.5. Recent Development
      *Similar details will be provided for the following companies
      • 9.5. Sanofi
      • 9.6. Olix Pharmaceuticals, Inc.
      • 9.7. Glaxosmithkline Plc.
      • 9.8. Benitec Biopharma
      • 9.9. Arbutus Biopharma Corporation
      • 9.10. Silence Therapeutics
      • 9.11. Rexahn Pharmaceuticals, Inc.
      • 9.12. Arrowhead Pharmaceuticals, Inc

      Report You Might be Interested

      Choose License Type

      • USD
      • GBP
      • EURO
      • INR
      Credit card Logo

      Happy To Assist You

      Have a Question? email us at

      info@datalibraryresearch.com

      Or Call Us On

      US +1 360 851 1343

      IND +91 880 579 4934